Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mesoblast (MESO) EBITDA (2016 - 2023)

Historic EBITDA for Mesoblast (MESO) over the last 9 years, with Q2 2023 value amounting to $3.0 billion.

  • Mesoblast's EBITDA rose 36.0% to $3.0 billion in Q2 2023 from the same period last year, while for Jun 2023 it was $687.7 million, marking a year-over-year increase of 542984.08%. This contributed to the annual value of -$62.0 million for FY2025, which is 553.46% down from last year.
  • According to the latest figures from Q2 2023, Mesoblast's EBITDA is $3.0 billion, which was up 36.0% from -$1.2 billion recorded in Q1 2023.
  • In the past 5 years, Mesoblast's EBITDA ranged from a high of $7.0 billion in Q2 2021 and a low of -$1.6 billion during Q1 2021
  • Its 5-year average for EBITDA is $298.4 million, with a median of -$541.9 million in 2019.
  • As far as peak fluctuations go, Mesoblast's EBITDA soared by 1956610.37% in 2020, and later tumbled by 1187267.58% in 2021.
  • Mesoblast's EBITDA (Quarter) stood at -$734.6 million in 2019, then surged by 101.37% to $10.0 million in 2020, then crashed by 9855.66% to -$978.4 million in 2021, then grew by 15.18% to -$829.8 million in 2022, then skyrocketed by 458.51% to $3.0 billion in 2023.
  • Its EBITDA was $3.0 billion in Q2 2023, compared to -$1.2 billion in Q1 2023 and -$829.8 million in Q4 2022.